@article{Meoni2020,
abstract = {Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from cytotoxic agents or small molecules against NSCLC, also tumor response may present with atypical features. Pseudoprogression (PP) is a distinct response pattern defined by a transient enlargement of the tumor burden, sustained by inflammatory cells and usually not associated with worsening of performance status (PS). Here the authors describe the case of a lung adenocarcinoma patient treated with pembrolizumab, who developed an early symptomatic PP with a dramatic global worsening of PS. Subsequently an improvement in general condition and a brilliant tumor response were observed. Tumor re-biopsy was collected after the treatment in order to support the identification of PP and to describe microenvironment modifications induce by immunotherapy.},
author = {Meoni, Giulia and Decarli, Nicola Libert{\`{a}} and Benucci, Maurizio and Raspanti, Claudio and Ribecco, Angela Stefania},
doi = {10.37349/etat.2020.00022},
issn = {2692-3114},
journal = {Exploration of Targeted Anti-tumor Therapy},
keywords = {immunotherapy,kirsten rat sarcoma,non-small cell lung cancer,performance status,pseudoprogression},
number = {5},
pages = {372--380},
title = {{Pseudoprogression in lung cancer: a case report}},
url = {https://www.explorationpub.com/Journals/etat/Article/100222},
volume = {1},
year = {2020}
}